Molecular Characterization and Genetic Subclassification Comparison of Diffuse Large B-Cell Lymphoma: Real-Life Experience with 74 Cases

Overview

Journal Pathobiology

Specialties Cell Biology
Pathology

Date 2023 Dec 21

PMID 38128501

Authors

Vanesa-Sindi Ivanova

Visar Vela

Stefan Dirnhofer

Michael Dobbie

Frank Stenner

Jan Knoblich

Alexandar Tzankov

Thomas Menter

Affiliations

Soon will be listed here.

Abstract

Introduction: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity. Lately, several algorithms achieving therapeutically and prognostically relevant DLBCL subclassification have been published.

Methods: A cohort of 74 routine DLBCL cases was broadly characterized by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) of the BCL2, BCL6, and MYC loci, and comprehensive high-throughput sequencing (HTS). Based on the genetic alterations found, cases were reclassified using two probabilistic tools - LymphGen and Two-step classifier, allowing for comparison of the two models.

Results: Hans and Tally's overall IHC-based subclassification success rate was 96% and 82%, respectively. HTS and FISH data allowed the LymphGen algorithm to successfully classify 11/55 cases (1 - BN2, 7 - EZB, 1 - MCD, and 2 - genetically composite EZB/N1). The total subclassification rate was 20%. On the other hand, the Two-step classifier categorized 36/55 cases, with 65.5% success (9 - BN2, 12 - EZB, 9 - MCD, 2 - N1, and 4 - ST2). Clinical correlations highlighted MCD as an aggressive subtype associated with higher relapse and mortality.

Conclusions: The Two-step algorithm has a better success rate at subclassifying DLBCL cases based on genetic differences. Further improvement of the classifiers is required to increase the number of classifiable cases and thus prove their applicability in routine diagnostics.

Citing Articles

Molecular Subtypes and the Role of TP53 in Diffuse Large B-Cell Lymphoma and Richter Syndrome.

Negara I, Tomuleasa C, Buruiana S, Efremov D Cancers (Basel). 2024; 16(12).

PMID: 38927876 PMC: 11201917. DOI: 10.3390/cancers16122170.

References

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

Xu-Monette Z, Wu L, Visco C, Tai Y, Tzankov A, Liu W . Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012; 120(19):3986-96. PMC: 3496956. DOI: 10.1182/blood-2012-05-433334. View

Campo E, Jaffe E, Cook J, Quintanilla-Martinez L, Swerdlow S, Anderson K . The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022; 140(11):1229-1253. PMC: 9479027. DOI: 10.1182/blood.2022015851. View

Wright G, Huang D, Phelan J, Coulibaly Z, Roulland S, Young R . A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020; 37(4):551-568.e14. PMC: 8459709. DOI: 10.1016/j.ccell.2020.03.015. View

Lacy S, Barrans S, Beer P, Painter D, Smith A, Roman E . Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 2020; 135(20):1759-1771. PMC: 7259825. DOI: 10.1182/blood.2019003535. View

Meyer P, Fu K, Greiner T, Smith L, Delabie J, Gascoyne R . Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2010; 29(2):200-7. PMC: 3058275. DOI: 10.1200/JCO.2010.30.0368. View

Smith A, Crouch S, Lax S, Li J, Painter D, Howell D . Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network. Br J Cancer. 2015; 112(9):1575-84. PMC: 4453686. DOI: 10.1038/bjc.2015.94. View

Pedrosa L, Fernandez-Miranda I, Perez-Callejo D, Quero C, Rodriguez M, Martin-Acosta P . Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma. Sci Rep. 2021; 11(1):1886. PMC: 7820010. DOI: 10.1038/s41598-020-80376-0. View

Chen R, Zhou D, Wang L, Zhu L, Ye X . MYD88 and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy. Ther Adv Hematol. 2022; 13:20406207211072839. PMC: 8808040. DOI: 10.1177/20406207211072839. View

10.

Tzankov A, Xu-Monette Z, Gerhard M, Visco C, Dirnhofer S, Gisin N . Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2013; 27(7):958-71. DOI: 10.1038/modpathol.2013.214. View

11.

Hwang H, Yoon D, Suh C, Park C, Huh J . Prognostic value of immunohistochemical algorithms in gastrointestinal diffuse large B-cell lymphoma. Blood Res. 2014; 48(4):266-73. PMC: 3894385. DOI: 10.5045/br.2013.48.4.266. View

12.

Teras L, DeSantis C, Cerhan J, Morton L, Jemal A, Flowers C . 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016; 66(6):443-459. DOI: 10.3322/caac.21357. View

13.

Rui L, Drennan A, Ceribelli M, Zhu F, Wright G, Huang D . Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2016; 113(46):E7260-E7267. PMC: 5135360. DOI: 10.1073/pnas.1610970113. View

14.

Campo E, Swerdlow S, Harris N, Pileri S, Stein H, Jaffe E . The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011; 117(19):5019-32. PMC: 3109529. DOI: 10.1182/blood-2011-01-293050. View

15.

Crotty S . Revealing T follicular helper cells with BCL6. Nat Rev Immunol. 2021; 21(10):616-617. DOI: 10.1038/s41577-021-00591-2. View

16.

Hans C, Weisenburger D, Greiner T, Gascoyne R, Delabie J, Ott G . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2003; 103(1):275-82. DOI: 10.1182/blood-2003-05-1545. View

17.

Shaffer 3rd A, Young R, Staudt L . Pathogenesis of human B cell lymphomas. Annu Rev Immunol. 2012; 30:565-610. PMC: 7478144. DOI: 10.1146/annurev-immunol-020711-075027. View

18.

Visco C, Tzankov A, Xu-Monette Z, Miranda R, Tai Y, Li Y . Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2012; 98(2):255-63. PMC: 3561433. DOI: 10.3324/haematol.2012.066209. View

19.

Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690. PMC: 6613387. DOI: 10.1038/s41591-018-0016-8. View

20.

Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View